Text: H.R.3327 — 116th Congress (2019-2020)All Information (Except Text)

There is one version of the bill.

Text available as:

Shown Here:
Introduced in House (06/18/2019)


116th CONGRESS
1st Session
H. R. 3327


To amend title XI of the Social Security Act to require that direct-to-consumer television advertisements for prescription drugs and biological products include the list price of such drugs and products, and for other purposes.


IN THE HOUSE OF REPRESENTATIVES

June 18, 2019

Mr. Rooney of Florida introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned


A BILL

To amend title XI of the Social Security Act to require that direct-to-consumer television advertisements for prescription drugs and biological products include the list price of such drugs and products, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Drug Price Transparency for Medicare Patients Act of 2019”.

SEC. 2. Requirement that direct-To-Consumer television advertisements for prescription drugs and biological products include list price of such drugs and products.

Part A of title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is amended by adding at the end the following new section:

“SEC. 1150C. Requirement that direct-To-Consumer television advertisements for prescription drugs and biological products include list price of such drugs and products.

“(a) In general.—Subject to subsection (b), the Secretary, acting through the Administrator of the Centers for Medicare & Medicaid Services (referred to in this section as the ‘Secretary’), shall require that each direct-to-consumer advertisement on television (including broadcast, cable, streaming, or satellite media) for a prescription drug or biological product for which payment is made available under title XVIII or XIX includes a written statement indicating the current list price for a 30-day supply of (or, if determined more appropriate by the Secretary, a typical course of treatment with) such drug or product as follows: ‘The list price for a [30-day supply of, or a typical course of treatment with] [name of prescription drug or biological product] is [current list price]. If you have health insurance that covers drugs, your cost may be different.’. Such statement shall be presented at the end of such an advertisement against a contrasting background for sufficient duration and in a size and style of font that allows such statement to be read easily.

“(b) Exception.—The requirement described in subsection (a) shall not apply with respect to a prescription drug or biological product that has a current list price less than $35 per month for a 30-day supply of, or a typical course of treatment with, such drug or product.

“(c) Identification of noncompliant drugs and products.—In the case that a direct-to-consumer advertisement described in subsection (a) does not include a written statement as required under such subsection and is not excepted with respect to such statement under subsection (b), the Secretary shall identify the prescription drug or biological product that is the subject of such advertisement as a drug or product advertised in violation of the requirement of subsection (a). The Secretary shall maintain a public list of all prescription drugs and biological products identified pursuant to the previous sentence.

“(d) Definitions.—In this section:

“(1) CURRENT LIST PRICE.—The term ‘current list price’, with respect to a prescription drug or biological product described in subsection (a) and a direct-to-consumer advertisement described in such subsection for such drug or product, means the wholesale acquisition cost (as defined in section 1847A(c)(6)) of such drug or product as of the first day of the quarter during which such advertisement is aired or otherwise broadcast.

“(2) TYPICAL COURSE OF TREATMENT.—The term ‘typical course of treatment’, with respect to a prescription drug or biological product described in subsection (a) and a direct-to-consumer advertisement described in such subsection for such drug or product, means the typical course of treatment associated with the primary indication addressed in such advertisement for which such drug or product is prescribed.”.